Keywords: Novartis, Tasigna, Japan approval, JAk inhibitor, Incyte, Myeloid leukemia, Myelofibrosis

Novartis’ Tasigna approved in Japan; JAK inhibitor INC424 meets primary Ph III endpoint

Article | 22 December 2010

Print This

It was a god news day for Swiss drug major Novartis (NOVN: VX) yesterday, as it received approval from Japan's ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in